The Current Ratio as of November 2024 (TTM) for Y-mAbs Therapeutics, Inc. (YMAB) is 2.92

According to Y-mAbs Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.92. This represents a change of -41.24% compared to the average of 4.96 of the last 4 quarters.

Y-mAbs Therapeutics, Inc. (YMAB) Historical Current Ratio (quarterly & annually)

How has YMAB Current Ratio performed in the past?

The mean historical Current Ratio of Y-mAbs Therapeutics, Inc. over the last ten years is 9.15. The current 2.92 Current Ratio has changed 3.09% with respect to the historical average. Over the past ten years (40 quarters), YMAB's Current Ratio was at its highest in in the September 2018 quarter at 17.82. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Y-mAbs Therapeutics, Inc. (YMAB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Y-mAbs Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Y-mAbs Therapeutics, Inc. (YMAB) Average Current Ratio

How has YMAB Current Ratio performed in the past?

The current Current Ratio of Y-mAbs Therapeutics, Inc. (YMAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Y-mAbs Therapeutics, Inc. (YMAB) Current Ratio vs. Peers

How is YMAB’s Current Ratio compared to its peers?

Y-mAbs Therapeutics, Inc.’s Current Ratio is less than TCR2 Therapeutics Inc. (2.96), less than Revolution Medicines, Inc. (15.42), less than Black Diamond Therapeutics, Inc. (6.87), greater than Atreca, Inc. (1.58), less than Passage Bio, Inc. (7.67), greater than bluebird bio, Inc. (0.68), greater than Mersana Therapeutics, Inc. (2.72), less than Zentalis Pharmaceuticals, Inc. (6.59), greater than Travere Therapeutics, Inc. (1.71), less than Generation Bio Co. (7.42), less than Kronos Bio, Inc. (8.49), less than Erasca, Inc. (16.79), less than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (30.24), less than Arcutis Biotherapeutics, Inc. (8.46), less than Icosavax, Inc. (18.06), less than Mirum Pharmaceuticals, Inc. (3.28), less than VectivBio Holding AG (9.14), less than Day One Biopharmaceuticals, Inc. (14.62), less than Vaxcyte, Inc. (17.88), less than Larimar Therapeutics, Inc. (13.10), less than Syndax Pharmaceuticals, Inc. (10.50), less than Merus N.V. (8.32), less than Sutro Biopharma, Inc. (3.41),

Build a custom stock screener for Y-mAbs Therapeutics, Inc. (YMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Y-mAbs Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Y-mAbs Therapeutics, Inc. (YMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Y-mAbs Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.